Investigation Report on China Entecavir Market 2020-2024

$2,600$3,900

Clear

Description

Description
The number of people infected with hepatitis B virus (HBV) exceeds 100 million in China by the end of 2019, among which 20-30 million suffering from chronic Hepatitis B. About 0.5 million Chinese is estimated to die of liver damage and liver cancer caused by chronic Hepatitis B every year, causing a loss of over CNY100 billion for society.
Entecavir, a drug of oral deoxyguanosine, was developed by Bristol-Myers Squibb and approved to enter the market by FDA in Mar. 2005. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd got CFDA’s approval at the end of 2005 and entered the Chinese market in early 2006, followed by many generic drugs which promote market growth greatly.
According to CRI’s market research, the annual sales value of entecavir in China rose from CNY1126 million in 2013 to CNY 1996 million in 2017 and decreased to CNY1264 in 2019. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd dominates the Chinese market with a share of over 40% in 2019 by sales value.
Compared with the original nucleoside analogue, entecavir has stronger antiviral effects, faster onset, fewer side effects and lower resistance rate, thus inhibiting HBV strongly and having a high barrier to drug resistance. Entecavir makes it possible for patients to start with monotherapy which could be successful over a long term. As is known to all, new drug’s entering the anti-HBV drug market is bound to pose a threat to old ones, forming a new competitive landscape.
According to CRI, Due to the lack of new antiviral drugs for Hepatitis B in a long time, the market demand is far from being satisfied. Therefore, entecavir is estimated to enjoy good market prospects and its sales volume will keep growing in the next few years. However, due to the decline in average prices, sales of entecavir in the Chinese market may continue to decline.

Topic covered
-sales value and volume of entecavir in China 2015-2019
– sales value and volume of entecavir by dosages in China 2015-2019
-competitive landscape of entecavir in Chinese market
-price of entecavir by regions in China
-price of entecavir made by different manufacturers in China
-market outlook of entecavir in China

Table of Contents

Table of Contents
1 Related Concepts of Entecavir
1.1 Indications for Entecavir
1.2 Development History of Entecavir in China
1.3 Governmental Approval for Entecavir in China

2 Survey on Sales Status of Entecavir in China, 2015-2019
2.1 Sales Value of Entecavir
2.1.1 Overall Sales Value of Entecavir in China
2.1.2 Sales Value of Entecavir by Region in China
2.2 Sales Volume of Entecavir
2.2.1 Overall Sales Volume of Entecavir in China
2.2.2 Sales Volume of Entecavir by Region in China
2.3 Sales of Entecavir by Dosage Form in China, 2015-2019
2.3.1 Sales of Entecavir Capsules in China
2.3.2 Sales of Entecavir Tablets in China

3 Major Manufacturers of Entecavir in China, 2015-2019
3.1 Market Share of Entecavir in China by Major Manufacturer
3.1.1 Market Share of Entecavir Manufacturers in China by Sales Value
3.1.2 Market Share of Entecavir Manufacturers in China by Sales Volume
3.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.’s Entecavir in China
3.3 Sino-American Shanghai Squibb Pharmaceuticals Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Sino-American Shanghai Squibb Pharmaceuticals Ltd.’s Entecavir in China
3.4 Jiangxi Qingfeng Pharmaceutical Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Jiangxi Qingfeng Pharmaceutical Co., Ltd.’s Entecavir in China
3.5 Suzhou Dawnrays Pharmaceutical Co., Ltd.
3.5.1 Enterprise Profile
3.5.2 Sales of Suzhou Dawnrays Pharmaceutical Co., Ltd.’s Entecavir in China
3.6 Fujian Cosunter Pharmaceutical Co., Ltd.
3.6.1 Enterprise Profile
3.6.2 Sales of Fujian Cosunter Pharmaceutical Co., Ltd.’s Entecavir in China

4 Prices of Entecavir in China, 2015-2020
4.1 Average Prices of Entecavir in China
4.1.1 Average Prices of Entecavir Capsules in China 2015-2019
4.1.2 Average Prices of Entecavir Tablets in China 2015-2019
4.2 Average Prices of Sino-American Shanghai Squibb Pharmaceuticals Ltd. ’ Entecavir (Baraclude)
4.3 Average Prices of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.’s Entecavir (Runzhong)
4.4 Average Prices of Jiangxi Qingfeng Pharmaceutical Co., Ltd. ’s Entecavir (Weiliqing)
4.5 Average Prices of Suzhou Dawnrays Pharmaceutical Co., Ltd. ’s Entecavir (Leiyide)
4.6 Average Prices of Fujian Cosunter Pharmaceutical Co., Ltd. ’s Entecavir (Enganding)

5 Market Outlook of Entecavir in China, 2020-2024
5.1 Forecast on Market Size
5.2 Forecast on Market Trend

Selected Charts
Chart Government Approval for Entecavir Dispersible Tablets in China by 2020
Chart Government Approval for Domestic-made Entecavir API in China by 2020
Chart Government Approval for Imported Entecavir API in China by 2020
Chart Government Approval for Domestic-made Entecavir Capsules in China by 2020
Chart Government Approval for Domestic-made Entecavir Tablets in China by 2020
Chart Sales Volume of Entecavir in China, 2015-2019
Chart Sales Value of Entecavir by Region in China, 2015-2019
Chart Sales Volume of Entecavir in China, 2015-2019
Chart Sales Volume of Entecavir by Region in China, 2015-2019
Chart Sales Value of Entecavir Capsules in China, 2015-2019
Chart Sales Volume of Entecavir Capsules in China, 2015-2019
Chart Sales Volume of Entecavir Tablets in China, 2015-2019
Chart Sales Volume of Entecavir Tablets in China, 2015-2019
Chart Market Share of Top 5 Entecavir Manufacturers by Sales Value in China, 2015-2019
Chart Market Share of Top 5 Entecavir Manufacturers by Sales Volume, 2015-2019
Chart Profile of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chart Sales Value of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.’s Entecavir, 2015-2019
Chart Sales Volume of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.’s Entecavir, 2015-2019
Chart Profile of Sino-American Shanghai Squibb Pharmaceuticals Ltd.
Chart Sales Value of Sino-American Shanghai Squibb Pharmaceuticals Ltd.’s Entecavir, 2013-201
Chart Sales Volume of Sino-American Shanghai Squibb Pharmaceuticals Ltd.’s Entecavir, 2015-2019
Chart Profile of Jiangxi Qingfeng Pharmaceutical Co., Ltd.
Chart Sales Value of Jiangxi Qingfeng Pharmaceutical Co., Ltd.’s Entecavir, 2015-2019
Chart Sales Volume of Jiangxi Qingfeng Pharmaceutical Co., Ltd.’s Entecavir, 2015-2019
Chart Profile of Suzhou Dawnrays Pharmaceutical Co., Ltd.
Chart Sales Value of Suzhou Dawnrays Pharmaceutical Co., Ltd.’s Entecavir, 2015-2019
Chart Sales Volume of Suzhou Dawnrays Pharmaceutical Co., Ltd.’s Entecavir, 2015-2019
Chart Prices of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.’s Entecavir in Parts of China in 2019-2020
Chart Prices of Sino-American Shanghai Squibb Pharmaceuticals Ltd.’s Entecavir in Parts of China in 2019-2020
Chart Prices of Jiangxi Qingfeng Pharmaceutical Co., Ltd.’s Entecavir (Weiliqing) in Parts of China in 2019-2020
Chart Prices of Suzhou Dawnrays Pharmaceutical Co., Ltd.’s Entecavir (Leiyide) in Parts of China in 2019-2020
Chart Prices of Fujian Cosunter Pharmaceutical Co., Ltd.’s Entecavir (Enganding) in Parts of China in 2019-2020
Chart Forecast on Size of China’s Entecavir Market, 2020-2024

Additional information

Publisher

Date Published

Pages

Charts

Format